Two posters demonstrated that povorcitinib showed durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. This content was ...
Gear Patrol on MSN
The North Face just released what is easily its nicest travel bag ever
Swapping out PVC for leather, this version of the Base Camp Duffel turns the iconic go-anywhere bag into a first-class ...
Starting a TNF inhibitor within 1 year of the onset of back pain may not improve clinical outcomes or drug retention compared ...
Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with axial SpA treated with TNF inhibitors had ...
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results